A randomized phase II study comparing gemcitabine plus nadroparine versus gemcitabine in patients with locally advanced or metastatic pancreatic carcinoma: The GEMFRAX trial

T. V. Voorthuizen,W. L. Vervenne,E. H. Van Daalen,Saffire S.K.S. Phoa,D. J. Gouma,Marco J. Bruno,D. J. Richel

A randomized phase II study comparing gemcitabine plus nadroparine versus gemcitabine in patients with locally advanced or metastatic pancreatic carcinoma: The GEMFRAX trial

2016

T. V. Voorthuizen
W. L. Vervenne
E. H. Van Daalen
Saffire S.K.S. Phoa
D. J. Gouma
Marco J. Bruno
D. J. Richel

4112 Background: Gemcitabine is considered to be the standard chemotherapy regimen for advanced pancreatic cancer. The advantage of gemcitabine over best supportive care however is limited. Preclin...

Keywords:

Pancreatic cancer
Pathology
Phases of clinical research
Oncology
Gemcitabine
Medicine
Nadroparine
Metastatic Pancreatic Carcinoma
Internal medicine
Chemotherapy regimen
locally advanced
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations